Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Gefitinib (DB00317)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00029003Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment